Findings from the PSUMMIT II Phase 3 investigational study showed patients with active psoriatic arthritis receiving Stelara (ustekinumab, Jannsen) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patients receiving either Stelara 45 mg or 90 mg achieved at least a 20 percent improvement in signs and symptoms, according to American College of Rheumatology criteria (ACR 20) at week 24, the primary endpoint, than did patients receiving placebo regardless of background methotrexate use. Among patients previously treated with TNF inhibitors, 36.7 percent of patients and 34.5 percent of patients receiving Stelara 45 mg or 90 mg, respectively, achieved ACR 20 at week 24 compared with 14.5 percent of patients receiving placebo. The data was presented at the 2012 Annual Meeting of the American College of Rheumatology in November.